First Trust Direct Indexing L.P. Has $2.64 Million Stock Holdings in Boston Scientific Co. (NYSE:BSX)

First Trust Direct Indexing L.P. grew its position in shares of Boston Scientific Co. (NYSE:BSXFree Report) by 9.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 38,506 shares of the medical equipment provider’s stock after purchasing an additional 3,482 shares during the quarter. First Trust Direct Indexing L.P.’s holdings in Boston Scientific were worth $2,637,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in BSX. Louisiana State Employees Retirement System bought a new position in shares of Boston Scientific during the fourth quarter worth about $5,116,000. Glenmede Trust Co. NA increased its holdings in Boston Scientific by 12.1% in the third quarter. Glenmede Trust Co. NA now owns 10,442 shares of the medical equipment provider’s stock worth $551,000 after purchasing an additional 1,123 shares in the last quarter. Sierra Summit Advisors LLC bought a new stake in Boston Scientific in the fourth quarter worth approximately $8,038,000. TD Asset Management Inc increased its holdings in Boston Scientific by 10.7% in the fourth quarter. TD Asset Management Inc now owns 1,615,932 shares of the medical equipment provider’s stock worth $93,417,000 after purchasing an additional 155,565 shares in the last quarter. Finally, HealthInvest Partners AB bought a new stake in Boston Scientific in the fourth quarter worth approximately $3,746,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on BSX shares. Deutsche Bank Aktiengesellschaft lifted their target price on Boston Scientific from $63.00 to $73.00 and gave the stock a “hold” rating in a report on Thursday, April 25th. Argus lifted their target price on Boston Scientific from $80.00 to $95.00 and gave the stock a “buy” rating in a report on Tuesday, May 28th. Needham & Company LLC reiterated a “buy” rating and issued a $82.00 target price on shares of Boston Scientific in a report on Tuesday, June 18th. Mizuho lifted their target price on Boston Scientific from $85.00 to $90.00 and gave the stock a “buy” rating in a report on Wednesday, May 15th. Finally, Royal Bank of Canada boosted their price objective on Boston Scientific from $78.00 to $82.00 and gave the company an “outperform” rating in a report on Thursday, April 25th. Three investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $77.41.

View Our Latest Report on Boston Scientific

Insider Buying and Selling at Boston Scientific

In related news, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $75.33, for a total transaction of $526,029.39. Following the transaction, the executive vice president now directly owns 45,628 shares of the company’s stock, valued at approximately $3,437,157.24. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $75.33, for a total transaction of $526,029.39. Following the transaction, the executive vice president now directly owns 45,628 shares in the company, valued at approximately $3,437,157.24. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Charles J. Dockendorff sold 3,946 shares of the firm’s stock in a transaction that occurred on Tuesday, May 7th. The stock was sold at an average price of $72.70, for a total value of $286,874.20. The disclosure for this sale can be found here. Insiders have sold a total of 72,259 shares of company stock valued at $5,344,014 in the last 90 days. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Trading Down 0.6 %

NYSE BSX opened at $76.11 on Friday. The firm has a market capitalization of $111.66 billion, a P/E ratio of 63.96, a PEG ratio of 2.62 and a beta of 0.78. The business has a fifty day simple moving average of $75.28 and a 200 day simple moving average of $68.07. Boston Scientific Co. has a 12 month low of $48.35 and a 12 month high of $77.99. The company has a current ratio of 1.66, a quick ratio of 1.14 and a debt-to-equity ratio of 0.47.

Boston Scientific (NYSE:BSXGet Free Report) last announced its quarterly earnings data on Wednesday, April 24th. The medical equipment provider reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.51 by $0.05. The firm had revenue of $3.86 billion during the quarter, compared to the consensus estimate of $3.68 billion. Boston Scientific had a return on equity of 16.39% and a net margin of 12.06%. On average, analysts predict that Boston Scientific Co. will post 2.32 EPS for the current fiscal year.

Boston Scientific Company Profile

(Free Report)

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Featured Articles

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSXFree Report).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.